Vitronectin receptors in vascular disorders.
Various integrin antagonist candidates, including antibodies, cyclic peptides, peptidomimetics and non-peptides, have been clinically evaluated and have been shown to successfully modulate certain disease processes. The most advanced integrin antagonists in clinical development include intravenous platelet alphaIIb/beta3 integrin antagonists, leukocyte alpha4/beta1 integrin antagonists and vascular alpha v/beta3 antagonists. This review will focus on the key role of the alpha v integrin (alpha v/beta3 and alpha v/beta5) in vascular disorders, such as angiogenesis-mediated disorders and vascular restenosis.
Mousa
Shaker A
SA
Albany College of Pharmacy, NY 12208-3492, USA. Mousas@acp.edu
D000818:Animals; D006083:Graft Occlusion, Vascular / Q000503:physiopathology; D006801:Humans; D039482:Integrin alpha5 / Q000187:drug effects; D039302:Integrin alphaVbeta3 / Q000187:drug effects / Q000502:physiology*; D016023:Integrins / Q000502:physiology; D010456:Peptides, Cyclic / Q000494:pharmacology; D015861:Retinal Neovascularization / Q000473:pathology; D020521:Stroke / Q000503:physiopathology; D014652:Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology
D039482:Integrin alpha5; D039302:Integrin alphaVbeta3; D016023:Integrins; D010456:Peptides, Cyclic